Development and Evaluation of Solid Lipid Nanoparticles of Raloxifene Hydrochloride for Enhanced Bioavailability

Table 2

Particle size and PDI of all the formulations.

Batch	Size (nm)	PDI	Zeta potential
A1	1406.3±245.50	1.13±1.05	+24.81
A2	1165.8±58.55	1.26±1.01	+26.12
A3	1101.0±51.05	1.66±2.53	+28.52
B1	925.7±55.80	0.27±0.14	+24.79
B2	631.0±47.75	0.30±.028	+20.02
B3	614.3±26.85	0.69±0.88	+20.83
C1	904.1±21.10	0.38±0.12	+29.36
C2	274.3±18.61	0.36±0.08	+16.25
C3	327.4±17.5	0.48±0.14	+18.25

Mean ± SD (𝑛=3).